ASH 2025 | Impact of additional cytogenetic abnormalities and complex karyotype on alloSCT outcomes in Ph+ ALL
In this video, Arnon Nagler, MD, Chaim Sheba Medical Center, Tel Aviv, Israel, discusses the findings of a registry-based retrospective analysis that assessed the impact of additional cytogenetic abnormalities and complex karyotype on outcomes of adult patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) undergoing allogeneic stem cell transplantation (alloSCT) in first complete remission. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are some data, old data, that additional chromosomal abnormalities and complex karyotypes in patients with Philadelphia positive ALL dictate poor outcome. And so 60% of the patients with Philadelphia positive ALL have additional chromosomal abnormalities. But most of these studies were not in the era of TKI. So we wanted to see if in the era of TKI in which all patients received tyrosine kinase inhibitor, pre- and post-transplant, all patients with Philadelphia ALL, what will be the impact of the additional chromosomal abnormalities and to our, I mean not surprise, but we were happy to see that the transplantation outcome of patients with Philadelphia positive with additional chromosomal abnormalities or complex karyotype was similar to the patient without additional chromosomal abnormalities or complex karyotype, speaking to the fact that if you receive TKI inhibitor pre- and post-transplant, it abrogates the negative impact of additional chromosomal abnormality...
There are some data, old data, that additional chromosomal abnormalities and complex karyotypes in patients with Philadelphia positive ALL dictate poor outcome. And so 60% of the patients with Philadelphia positive ALL have additional chromosomal abnormalities. But most of these studies were not in the era of TKI. So we wanted to see if in the era of TKI in which all patients received tyrosine kinase inhibitor, pre- and post-transplant, all patients with Philadelphia ALL, what will be the impact of the additional chromosomal abnormalities and to our, I mean not surprise, but we were happy to see that the transplantation outcome of patients with Philadelphia positive with additional chromosomal abnormalities or complex karyotype was similar to the patient without additional chromosomal abnormalities or complex karyotype, speaking to the fact that if you receive TKI inhibitor pre- and post-transplant, it abrogates the negative impact of additional chromosomal abnormality. And also it was interesting, the patients with additional chromosomal abnormality achieved better MRD negativity pre-transplant than in patients without additional chromosomal abnormalities. And this can explain some of the data that there is no effect on transplantation outcome.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
